CIK联合化疗治疗晚期食管癌的疗效观察

目的:探讨CIK联合FP化疗治疗进展期食管癌的可行性,安全性及近期疗效。方法:观察组21例采用CIK联合FP方案:DDP 30 mg/m2,静滴,第1~3 d,5-FU500 mg/m2,静滴,第1~5 d,化疗前抽血行CIK细胞培养,12~14 d培养结束后回输,21 d为1周期。对照组25例采用FP方案同观察组。观察两组患者疗效,生存质量,免疫功能的变化。结果:两组46例患者均完成治疗计划。两组均无CR病例。对照组PR 8例,SD 8例,PD 9例,有效率32%,临床获益率64%,CIK联合FP观察组,PR 10例,SD 7例,PD 4例,有效率47.6%,临床获益率80.95%。两组近期疗效有统计学差异(P<0.05)。疗程结束后2周,观察组治疗前后患者外周血中淋巴细胞表型进行分析显示,患者免疫功能状态较治疗前有明显改善。结论:CIK联合化疗治疗食管癌是一种安全可行,有效的治疗模式。

Clinical effects on chemotherapy combined with CIK for patients with advanced oesophageal carcinoma

Objective: To explore the feasibility,safety,and efficacy of CIK combinated chemotherapy in the treatment of advanced oesophageal carcinoma.Methods: 21 patients were treated with CIK combined with FP regimen,5-Fu 500 mg/m2,iv,1-5 d;DDP 30 mg/m2,iv,1-3 d;CIK cells were induced and then were transfused back to the patients.The changes of tumor,life quality,and immunity indexes were observed.Control group only were treated with FP regimen.Results: All patients completed the therapy regimen successfully.None complete remission was obsevered in the two groups.While in the control group,the clinical benefical rate was 64%,with PR 32%. In the study group,the clinical benefical rate was 80.95%,with PR 47.6%.It has significant differences between the two groups in terms of clinical benefical rate,life quality and immunity indexes.Conclusion: CIK combinated with FP chemotherapy regimen is a safe and feasible approach to advanced oesophageal carcinoma.